STAT

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Source: Mark J. Terrill/AP

Amgen will charge $6,900 a year for a new drug that can spare migraine sufferers a few headaches each month, a price that comes in well below Wall Street expectations as the company hopes to avoid the payer backlash that has hamstrung recent drug launches.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min read
Opinion: As The Need For Organ Transplants Grows, The Number Of Transplant Physicians Dwindles
Medical training has been long been characterized as a "grand bargain" in which trainees make personal sacrifices with the expectation of a better life later. But that's a deal many…
STAT2 min read
Alexion Acquiring Achillion To Expand Reach Into Rare, Immune-related Disease
Alexion Pharmaceuticals said that it will acquire Achillion Pharmaceuticals to expand its pipeline of experimental drugs targeting rare diseases of the immune system.
STAT9 min read
The ‘Unbelievable Journey’ Of CRISPR, Now On Netflix
"Unnatural Selection," a four-part docuseries debuting today, dissects the stories, science, and ethics behind genome editing.